提供支持Genolmmune Therapeutics received a 100 million yuan A+ round of financing. This round of financing was led by Hillhouse Ventures, with participation from four investment institutions including Optics-Valley Venture, Daxiang Venture Capital, KnowCell, and Qianluo Yanan Investment.
As a BGI company, GenoImmune Therapeutics is committed to tumor immune cell therapy of high-tech bio technology enterprises. It is making full use of advanced life digitalization technology to stimulate the body's immune system to fight tumor vitality and develop a new advanced prevention and treatment plan targeting tumor specific antigen, so that patients can benefit from it.
Since 2011, GenoImmune has focused on the research and development of tumor genome, bioinformatics technology and tumor immunity. GenoImmune has published 32 international high level articles and 3 articles. After 5 years of research and precipitation, it developed the core technology of NeoTT Neoantigen based T cell Therapy, that is, extract tumor specific antigen from massive tumor life information, and create bioproducts for cancer targeted therapy. NeoTT technology has 5 invention patents.
At the same time, GenoImmune has 1300 square meters of GMP cell preparation centers, and have been certified by ISO9001, ISO14001 and OHSAS18001. Based on the core technology of NeoTT, and US Department of biotherapy of Affiliated Tumor Hospital of Zhongshan University jointly launched a tumor specific antigen peptide induced DC-CTL cells in phase I clinical studies, DC-CTL cells were treated by recruiting 24 patients with advanced melanoma cases, safety verification and preliminary observation on the effectiveness of NeoTT.
The Company has a team of experts with rich experience in the industry, the core members of the national leading talent bioinformatics experts, pharmaceutical drug development for many years of experience in senior immunology experts, life data mining and the transformation of clinical medical experts.
渝公网安备 50011202502165号
